Physician profile
Miranda Sanchez
NPI 1831698273
$4,503.49
in general payments reported to CMS, 2019-2025
17 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $724 · 2022: $1,044 · 2023: $1,951 · 2024: $665 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $853.93 | 2022-2023 | Acuvue |
| Otsuka America Pharmaceutical, INC. | $501.77 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $487.89 | 2021-2024 | |
| Alkermes, INC. | $480.14 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $383.37 | 2021-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Indivior INC. | $273.04 | 2022-2024 | Perseris |
| Lundbeck LLC | $262.69 | 2021-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $262.33 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $228.39 | 2021-2023 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $216.31 | 2021-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $204.54 | 2022-2025 | Trintellix |
| Corium, LLC | $132.77 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $87.22 | 2021-2022 | |
| Axsome Therapeutics, INC. | $50.42 | 2024 | Auvelity |
| Owp Pharmaceuticals, INC. | $36.44 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $26.60 | 2023 | |
| Vanda Pharmaceuticals INC. | $15.64 | 2023 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.